253 related articles for article (PubMed ID: 7533611)
1. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A.
Hu DE; Fan TP
Br J Pharmacol; 1995 Jan; 114(2):262-8. PubMed ID: 7533611
[TBL] [Abstract][Full Text] [Related]
2. Correlation of 133Xe clearance, blood flow and histology in the rat sponge model for angiogenesis. Further studies with angiogenic modifiers.
Hu DE; Hiley CR; Smither RL; Gresham GA; Fan TP
Lab Invest; 1995 May; 72(5):601-10. PubMed ID: 7538184
[TBL] [Abstract][Full Text] [Related]
3. Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin.
Fujii E; Irie K; Ohba K; Ogawa A; Yoshioka T; Yamakawa M; Muraki T
Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):475-80. PubMed ID: 9349634
[TBL] [Abstract][Full Text] [Related]
4. Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells.
Sakamoto T; Ishibashi T; Kimura H; Yoshikawa H; Spee C; Harris MS; Hinton DR; Ryan SJ
Invest Ophthalmol Vis Sci; 1995 May; 36(6):1076-83. PubMed ID: 7537258
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat.
Hu DE; Fan TP
Inflammation; 1995 Feb; 19(1):39-54. PubMed ID: 7535750
[TBL] [Abstract][Full Text] [Related]
6. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants.
Majima M; Hayashi I; Muramatsu M; Katada J; Yamashina S; Katori M
Br J Pharmacol; 2000 Jun; 130(3):641-9. PubMed ID: 10821793
[TBL] [Abstract][Full Text] [Related]
7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
8. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.
Waltenberger J; Mayr U; Frank H; Hombach V
J Mol Cell Cardiol; 1996 Jul; 28(7):1523-9. PubMed ID: 8841939
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor.
Mandriota SJ; Pepper MS
J Cell Sci; 1997 Sep; 110 ( Pt 18)():2293-302. PubMed ID: 9378778
[TBL] [Abstract][Full Text] [Related]
10. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
11. VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production.
Yang HT; Yan Z; Abraham JA; Terjung RL
Am J Physiol Heart Circ Physiol; 2001 Mar; 280(3):H1097-104. PubMed ID: 11179052
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide suppresses bFGF- and IL-1-alpha-mediated but not VEGF165-mediated angiogenesis in natively vascularized mammalian tissue.
Norrby K
APMIS; 1998 Dec; 106(12):1142-8. PubMed ID: 10052722
[TBL] [Abstract][Full Text] [Related]
13. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane.
Wilting J; Christ B; Bokeloh M; Weich HA
Cell Tissue Res; 1993 Oct; 274(1):163-72. PubMed ID: 7694800
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants.
Hori Y; Hu DE; Yasui K; Smither RL; Gresham GA; Fan TP
Br J Pharmacol; 1996 Aug; 118(7):1584-91. PubMed ID: 8842418
[TBL] [Abstract][Full Text] [Related]
17. A novel in vitro assay for human angiogenesis.
Brown KJ; Maynes SF; Bezos A; Maguire DJ; Ford MD; Parish CR
Lab Invest; 1996 Oct; 75(4):539-55. PubMed ID: 8874385
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis.
Tomanek RJ; Sandra A; Zheng W; Brock T; Bjercke RJ; Holifield JS
Circ Res; 2001 Jun; 88(11):1135-41. PubMed ID: 11397779
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
20. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas.
Muramatsu M; Yamada M; Takai S; Miyazaki M
Br J Pharmacol; 2002 Oct; 137(4):554-60. PubMed ID: 12359638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
